Angiotensin II Converting Enzyme (ACE2) Activity Assay试剂盒(Fluorometric) (ab273297)
Key features and details
- Assay type: Enzyme activity (quantitative)
- Detection method: Fluorescent
- Platform: Microplate
- Sample type: Adherent cells, Suspension cells, Tissue
- Sensitivity: 400 µU
概述
-
产品名称
Angiotensin II Converting Enzyme (ACE2) Activity Assay试剂盒(Fluorometric)
参阅全部 ACE2 试剂盒 -
检测方法
Fluorescent -
样品类型
Tissue, Adherent cells, Suspension cells -
检测类型
Enzyme activity (quantitative) -
灵敏度
400 µU -
实验步骤
Multiple steps standard assay -
产品概述
Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (ab273373) utilizes the ability of an active ACE2 to cleave a synthetic MCA based peptide substrate to release a free fluorophore. The released MCA can be easily quantified using a fluorescence microplate reader. We also provide an ACE2 specific inhibitor that can differentiate the ACE2 activity from other proteolytic activity. The kit can detect as low as 0.4 mU. The assay kit is simple and can be used in a high-throughput format. A negative control should be run for each sample to differentiate ACE2 activity from other proteolytic activity in your sample
-
说明
This product is manufactured by BioVision, an Abcam company and was previously called K897 Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric). K897-100 is the same size as the 100 test size of ab273297.
The Safety Datasheet for this product has been updated for certain countries. Please check the current version in the SDS download section.
-
平台
Microplate
性能
-
存放说明
Store at -20°C. Please refer to protocols. -
组件 100 tests 100 tests ACE2 Dilution Buffer 1 x 1.5ml 1 x 1.5ml ACE2 Inhibitor 1 x 50µl 1 x 50µl ACE2 Lysis Buffer 1 x 50ml 1 x 50ml ACE2 Enzyme 1 x 20µl 1 x 20µl ACE2 Substrate 1 x 200µl 1 x 200µl Assay Buffer XI 1 x 25ml 1 x 25ml MCA Standard 1 x 25µl 1 x 25µl -
研究领域
-
功能
Carboxypeptidase which converts angiotensin I to angiotensin 1-9, a peptide of unknown function, and angiotensin II to angiotensin 1-7, a vasodilator. Also able to hydrolyze apelin-13 and dynorphin-13 with high efficiency. May be an important regulator of heart function. In case of human coronaviruses SARS and HCoV-NL63 infections, serve as functional receptor for the spike glycoprotein of both coronaviruses. -
组织特异性
Expressed in endothelial cells from small and large arteries, and in arterial smooth muscle cells. Expressed in lung alveolar epithelial cells, enterocytes of the small intestine, Leydig cells and Sertoli cells (at protein level). Expressed in heart, kidney, testis, and gastrointestinal system. -
序列相似性
Belongs to the peptidase M2 family. -
翻译后修饰
N-glycosylation on Asn-90 may limit SARS infectivity. -
细胞定位
Secreted and Cell membrane. - Information by UniProt
-
别名
- ACE 2
- ACE related carboxypeptidase
- ACE-related carboxypeptidase
see all
图片
-
MCA Standard Curve
Typical standard curve – data provided for demonstration purposes only. A new standard curve must be generated for each assay performed.
MCA Standard Curve (0-300 pmol), error bars indicate SD (n=3).
-
Kinetic activity curvesKinetic activity curves using different amounts of ACE2 Positive Control in the assay.
-
ACE2 Activity in Tissue SamplesACE2 activity was measured for different types of rat tissue samples (total protein in lung and kidney; 17 µg and 23 µg respectively), and human kidney tissue sample (10 µg total protein) in presence (+ Inhibitor) and absence (- Inhibitor) of ACE2 Inhibitor.
-
Spiked ACE2 activity and inhibition measured in HEK-293 cell lysateSpiked ACE2 activity and inhibition measured in HEK-293 cell lysate (total protein: 37 µg).
数据表及文件
-
SDS download
-
Datasheet download
文献 (10)
ab273297 被引用在 10 文献中.
- Brevini T et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature 615:134-142 (2023). PubMed: 36470304
- Tu WJ et al. In vivo inhibition of nuclear ACE2 translocation protects against SARS-CoV-2 replication and lung damage through epigenetic imprinting. Nat Commun 14:3680 (2023). PubMed: 37369668
- Li Z et al. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. Cell Metab 34:424-440.e7 (2022). PubMed: 35150639
- Taha Z et al. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen. Mol Ther 30:2998-3016 (2022). PubMed: 35526097
- Sarker H et al. Glucocorticoids Bind to SARS-CoV-2 S1 at Multiple Sites Causing Cooperative Inhibition of SARS-CoV-2 S1 Interaction With ACE2. Front Immunol 13:906687 (2022). PubMed: 35784352
- Fast L et al. Fluorescence-Based Measurements of Membrane-Bound Angiotensin Converting Enzyme 2 Activity Using Xenopus Laevis Oocytes. Biosensors (Basel) 12:N/A (2022). PubMed: 36004997
- Bhullar KS et al. Structurally Modified Bioactive Peptide Inhibits SARS-CoV-2 Lentiviral Particles Expression. Pharmaceutics 14:N/A (2022). PubMed: 36297481
- Wang Y et al. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice. FASEB J 35:e21419 (2021). PubMed: 33566370
- Sène MA et al. Haplotype-resolved de novo assembly of the Vero cell line genome. NPJ Vaccines 6:106 (2021). PubMed: 34417462
- Svilenov HL et al. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Res 196:105197 (2021). PubMed: 34774603